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Abstract 
Background: Clinical guidelines vary with respect to the optimal monitoring frequency of HIV-positive 
individuals. We compared dynamic monitoring strategies based on evolving CD4 cell counts in 
virologically suppressed HIV-positive individuals.  
Methods: We used data from prospective studies of HIV-positive individuals in Europe and the Americas 
in the HIV-CAUSAL Collaboration and The Center for AIDS Research Network of Integrated Clinical 
Systems. We compared three monitoring strategies, which differ with respect to the CD4 cell count 
threshold that is used to measure CD4 cell count and HIV-RNA every 3-6 months (when below the 
threshold) or every 9-12 months (when above the threshold). The strategies were defined by the 
thresholds 200, 350, and 500 cells/µl. We estimated hazard ratios of death and of AIDS-defining illness or 
death, risk ratios of virologic failure, and mean differences in CD4 cell count using inverse probability 
weighting to adjust for baseline and time-varying confounders.   
Findings: 47,635 eligible individuals initiated a cART regimen between January, 2000 and November, 
2015 and met the eligibility criteria for our study. During follow-up, CD4 cell count and HIV-RNA were 
measured on average every 4 and 3.8 months, respectively. 464 individuals died (107 in threshold 200 
strategy, 157 in threshold 350, and 200 in threshold 500) and 1,091 had AIDS-defining illnesses or died 
(267 in threshold 200 strategy, 365 in threshold 350, and 459 in threshold 500). Compared with threshold 
500, the mortality hazard ratio (95% CI) was 1.05 (0.86, 1.29) for threshold 200 and 1.02 (0.91, 1.14) for 
threshold 350. Corresponding estimates for death or AIDS-defining illness were 1.08 (0.95, 1.22) and 
1.03 (0.96, 1.12), respectively. The respective 24-month risk ratios (95% CI) of virologic failure (HIV-
RNA>200 copies/ml) were 2.01 (1.17, 3.43) and 1.24 (0.89, 1.73) and 24-month mean CD4 cell count 
differences (95% CIs) were 0.4 (-25.5, 26.3) cells/µl and -3.5 (-16.0, 8.9) cells/µl. 
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Interpretation: Our findings suggest that decreasing monitoring to annually when CD4 cell count>200 
cells/µl compared with >500 cells/µl does not worsen the short-term clinical and immunologic outcomes 
of virologically suppressed HIV-positive individuals, but more frequent virologic monitoring may be 
necessary to decrease the risk of virologic failure. Further follow-up is needed to establish the long-term 
safety of these strategies.   
Funding: National Institutes of Health 
Keywords: CD4 cell count, HIV-RNA, monitoring, mortality, observational studies 
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Introduction 
The overall benefits of immunologic and virologic monitoring for the management of HIV-positive 
individuals are widely accepted, but the frequency with which CD4 cell count and HIV-RNA should be 
monitored remains unknown.1-6 
Clinical guidelines recommend dynamic strategies in which monitoring frequency among virologically 
suppressed individuals on combined antiretroviral therapy (cART) can be decreased when their CD4 cell 
count increases. The guidelines, however, vary with regards to the CD4 cell threshold at which this 
decrease should occur.7-10 For example, the European AIDS Clinical Society recommends that CD4 cell 
monitoring frequency can be decreased among stable individuals with a CD4 cell count>350 cells/µl and 
HIV-RNA<50 copies/ml.9 In comparison, the British HIV Association advises that CD4 monitoring 
frequency can be decreased in patients with a CD4 cell count>200 cells/µl and HIV-RNA<50 copies/ml 
for 1 year. Guidelines for thresholds at which HIV-RNA monitoring frequency can be decreased are 
generally lacking.7-10 
Two randomized trials11,12 and several observational studies,13-16 including ours,17 focused on CD4 cell 
and HIV-RNA monitoring strategies in which monitoring frequency is independent of an individual’s 
time-varying CD4 cell count. While these studies found no clinical harm for annual13-17 or biannual11,12 
monitoring, further follow-up is needed to establish the long-term safety. Moreover, none of these studies 
evaluated the effectiveness of the dynamic monitoring strategies recommended by the guidelines with 
respect to virologic and clinical outcomes. 
Here, we evaluate the effect of CD4 cell count and HIV-RNA dynamic monitoring strategies on clinical, 
virologic, and immunologic outcomes in virologically suppressed HIV-positive individuals using 
observational data from two collaborations of prospective cohort studies from high-income countries. Our 
5 
 
analyses study whether information about an individual’s time-varying CD4 cell count can provide any 
additional benefit in determining when monitoring frequency can be decreased.  
Methods  
Study population 
The HIV-CAUSAL Collaboration includes prospective cohort studies from 6 European countries and the 
Americas.18 The individual cohort studies are FHDH-ANRSC04 (France), ANRS PRIMO (France), 
ANRS SEROCO (France), ANRS CO3-Aquitaine (France), UK CHIC (United Kingdom), UK Register of 
HIV Seroconverters (United Kingdom), ATHENA (the Netherlands), SHCS (Switzerland), PISCIS 
(Spain), CoRIS/CoRIS-MD (Spain), GEMES (Spain), VACS (United States), AMACS (Greece), IPEC 
(Brazil) and SAC (Canada). The Center for AIDS Research (CFAR) Network of Integrated Clinical 
Systems (CNICS) contains clinical data from inpatient and outpatient encounters of HIV-infected 
individuals at 8 U.S. sites: Case Western Reserve University, Fenway Community Health Clinic, Johns 
Hopkins University, University of Alabama at Birmingham, University of California at San Diego, 
University of California at San Francisco, University of North Carolina, and University of Washington.19 
All cohorts included in the HIV-CAUSAL and CNICS Collaborations are based on data collected 
prospectively for clinical purposes.  
Our analysis was restricted to antiretroviral-therapy naïve individuals18 who initiated a cART regimen in 
2000 or later consisting of at least two nucleoside reverse transcriptase inhibitors plus one or more of the 
following: protease inhibitor, nonnucleoside reverse transcriptase inhibitor, entry/fusion inhibitor, or 
integrase inhibitor. Regimens consisting of abacavir or tenofovir with two or more additional nucleoside 
reverse transcriptase inhibitors were also considered cART regimens (2.8% of all eligible regimens). 
Individuals with confirmed virologic suppression (two consecutive HIV-RNA≤200 copies/ml) within 12 
months of initiating cART were eligible for inclusion in our study. Baseline was defined as the date of 
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confirmed virologic suppression following cART initiation. Our analysis was further restricted to 
individuals who met the following criteria at baseline: age 18 years or older and no pregnancy (when 
information was available), no history of AIDS (defined as the onset of any Category C AIDS-defining 
illness),20 and a CD4 cell count measured within the previous three months. 
Outcomes  
We considered two clinical outcomes: all-cause mortality and a combined end point of AIDS-defining 
illness or death. The date of death was identified using a combination of national and local mortality 
registries and clinical records, as described elsewhere,18,19 and AIDS-defining illnesses were ascertained 
by the treating physicians. For each individual, follow-up ended at the event of interest, pregnancy (if 
known), or the cohort-specific administrative end of follow-up (ranging from December, 2009, to 
November, 2015), whichever occurred earlier. We also considered virologic failure (HIV-RNA>200 
copies/ml) at 24 ± 2 months and mean CD4 cell count over the first 24 months of follow-up as outcomes.  
Monitoring strategies 
We compared three monitoring strategies, which differ with respect to the CD4 cell count threshold that is 
used to measure CD4 cell count and HIV-RNA every 3-6 months (when below the threshold) or every 9-
12 months (when above the threshold). The three strategies were defined by the thresholds 200, 350 and 
500 cells/µl (Figure 1) so we refer to the strategies as “threshold 200”, “threshold 350”, and “threshold 
500”, respectively. All three strategies further require individuals to be monitored once every 3-6 months 
when HIV-RNA>200 copies/ml or after diagnosis of an AIDS-defining illness. Each strategy allowed an 
additional one month before and after each monitoring window (e.g. 3-6 ± 1), so the grace period was a 
total of 5 months.  
At baseline, all individuals included in our study had data consistent with each of the three monitoring 
strategies because an individual’s evolving covariates are unknown at this point. To emulate a 
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hypothetical randomized trial -- a target trial21 -- where each eligible individual is randomly assigned to 
one of the three monitoring strategies, we created an expanded dataset by making 3 exact replicates of 
each individual (1 per strategy). If and when an individual’s data were no longer consistent with a given 
strategy, we artificially censored the corresponding replicate at that time. Replicates were censored when 
they were monitored sooner than indicated by their strategy or when they were not monitored soon 
enough. Replicates were also censored when a CD4 measurement was recorded without a HIV-RNA 
measurement, or vice versa, which occurred in fewer than 13% of months in which a measurement was 
recorded. Examples of the replication and censoring process have been described elsewhere.17,22  
Statistical analysis     
We fit a pooled logistic regression model to the expanded dataset to estimate the mortality hazard ratio for 
monitoring strategy (a 3-level categorical variable with “threshold 500” as the reference) conditional on 
time of follow-up (restricted cubic splines with 4 knots at 1, 6, 12, and 24 months) and the following 
baseline covariates: sex, CD4 cell count (≤200, 201-350, 351-500, ≥501 cells/µl), years since HIV 
diagnosis (<1, 1-4, ≥5 years, unknown), race (white, black, other or unknown), geographic origin (N. 
America/W. Europe, Sub-Saharan Africa, other, unknown), acquisition group (heterosexual, homosexual 
or bisexual, injection drug use, other or unknown), calendar year (restricted cubic splines with 3 knots at 
2001, 2007 and 2011), age (restricted cubic splines with 3 knots at 25, 39 and 60 years), cohort, and 
months from cART initiation to virologic suppression (2-4, 5-8, ≥9). We conducted an identical analysis 
to estimate the hazard ratio of the combined endpoint of AIDS-defining illness or death. Because the 
monthly probability of an event is small, the parameters of our pooled logistic model closely approximate 
the parameters of a Cox proportional hazards model.23,24  
To estimate absolute risks for the two clinical outcomes under each monitoring strategy, we fit a pooled 
logistic regression model like the one described above that also included product terms between 
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monitoring strategy and follow-up time. The model’s predicted values were used to estimate 24-month 
survival and 24-month AIDS-free survival curves for each strategy.  
The process of artificial censoring could induce time-varying selection bias. For example, an individual 
whose CD4 drops from 500 cells/µl to 250 cells/µl and is subsequently monitored more frequently will be 
artificially censored from the “threshold 200” strategy. To adjust for the potential selection bias,25 we 
weighted each replicate at each time by the inverse of the probability of having one’s own observed 
monitoring history. For an explanation of why the probability of monitoring can be used to estimate the 
probability of remaining uncensored, please see Cain et al. 2010.22 To estimate the inverse probability 
weights, we fit a pooled multinomial regression model for monitoring (a 3-level categorical variable) in 
the original, unexpanded study population. The model included the previously listed covariates as well as 
the most recent measurement of the following time-varying covariates: CD4 cell count (restricted cubic 
splines with 5 knots at 200, 350, 500, 650, and 1000 cells/µl), HIV-RNA (≤200, 201-999, 1,000-9,999, 
≥10,000 copies/ml), diagnosis of an AIDS-defining illness (when the outcome was all-cause mortality), 
proportion of months of follow-up from baseline to the current observation with a CD4 cell count 
measurement (restricted cubic splines with 3 knots at 0.2, 0.3 and 0.5) and months since the last CD4 cell 
count measurement (restricted cubic splines with 3 knots at 1, 4 and 7). Because of the dynamic nature of 
the strategies under consideration, we computed partially stabilized weights and weights corresponding to 
monitoring strategies where individuals are monitored with a uniform probability during the grace period 
(Appendix Page 2).17,22 The weights were truncated at the 99th percentile,26 but truncation had little effect 
on the estimates. Under each strategy, any replicate who did not have a CD4 cell count and HIV-RNA 
measurement at least every 13 months was artificially censored, and so additional adjustment for loss to 
follow-up was not necessary. 
For the outcome virologic failure, we fit a weighted Poisson regression model27 with the same covariates 
as above to estimate the risk ratio of virologic failure (HIV-RNA>200 copies/ml) at 24 months for 
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monitoring strategy among those with measurements at 24 ± 2 months. We used additional inverse 
probability weights to adjust for censoring due to not having an HIV-RNA measurement at 24 ± 2 
months. We varied the definitions of virologic suppression and failure and estimated the risk of virologic 
failure at 18 ± 2 months in secondary analyses. To estimate mean CD4 cell count, we fit a weighted log-
linear regression model for mean CD4 cell count that further included product terms between monitoring 
strategy and follow-up time. The model’s predicted values were used to estimate 24-month mean CD4 
cell count curves. We performed several sensitivity analyses, which are described in the Appendix (Page 
1). We used nonparametric bootstrapping with 500 samples to compute 95% confidence intervals for all 
of our estimates. 
Role of the funding source 
The funders had no role in study design, data collection and analysis, data interpretation, or preparation of the 
manuscript. The corresponding author had full access to all data in the study and had final responsibility for the 
decision to submit for publication.  
Results  
Table 1 shows the baseline characteristics of the 47,635 eligible individuals who initiated a cART 
regimen between January, 2000 and November, 2015 and met the eligibility criteria for our study. The 
analyses presented here are based on data pooled in November, 2015. During follow-up, CD4 cell count 
and HIV-RNA were measured on average every 4 and 3.8 months, respectively, and HIV-RNA was 
measured in more than 94% of months in which CD4 cell count was measured. In a given month, having 
CD4 cell count measured was associated with older age, lower CD4 cell counts and higher HIV-RNA in 
previous months, earlier calendar years, and a history of more frequent monitoring (Appendix Page 3). 
Among the individuals who had data consistent with at least one monitoring strategy for one complete 
year, those following the “threshold 500” strategy had higher baseline and current CD4 cell counts, were 
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more likely to be homo/bisexual, and were less likely to have been diagnosed with HIV infection in the 
previous year, compared with individuals following the other strategies (Table 1). The rate of treatment 
switching was smaller for those following the “threshold 200” strategy and similar for those following the 
“threshold 350” strategy, compared with those following the “threshold 500” strategy (Appendix Page 5). 
Figure 2 shows the number of uncensored individuals who followed each of the three monitoring 
strategies over time in the all-cause mortality analysis. Appendix Figure 1 (Page 8) show the proportion of 
individuals who followed each monitoring strategy over follow-up time with HIV-RNA≤200 copies/ml, 
without a diagnosis of an AIDS-defining illness, and with CD4 cell count greater than the corresponding 
strategy’s threshold (i.e. monitored every 9-12 months). The proportion of individuals with a CD4 cell 
count above each strategy’s threshold decreased over follow-up time; a large amount of the artificial 
censoring was due to individuals being monitored more frequently than every 9-12 months.  
Death and AIDS-defining illness 
During follow-up there were 464 deaths and 1,091 cases of the combined endpoint of AIDS-defining 
illness or death. On average, each death contributed to 2.2 strategies and each case of AIDS-defining 
illness or death contributed to 2.3 strategies. Among those with the event of interest, the median (IQR) 
time from baseline to event was 6 (2,15) months for all-cause mortality and 5 (1,11) months for death or 
AIDS-defining illness.  
The mortality hazard ratio (95% CI) was 1.05 (0.86, 1.29) for “threshold 200” and 1.02 (0.91, 1.14) for 
“threshold 350”, compared with “threshold 500” (Table 2). Compared with “threshold 500”, the hazard 
ratios for death or AIDS-defining illness were 1.08 (0.95, 1.22) for “threshold 200” and 1.03 (0.96, 1.12) 
for “threshold 350”. If we had not adjusted for time-varying confounding, the hazard ratio estimates 
would have been similar (Appendix Page 6). None of the sensitivity analyses yielded appreciably 
different results (data not shown).  
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The estimated 24-month survival (95% CI) was 0.99 (0.99, 1.00) for “threshold 200”, 0.99 (0.99, 0.99) for 
“threshold 350” and 0.99 (0.99, 0.99) for “threshold 500”. The corresponding estimates for 24-month 
AIDS-free survival (95% CI) were 0.98 (0.97, 0.99), 0.98 (0.97, 0.98) and 0.98 (0.98, 0.99) (Figure 3).  
Virologic failure 
295 individuals experience virologic failure (HIV-RNA>200 copies/ml) at 24 ± 2 months. Compared with 
“threshold 500”, the risk ratio for virologic failure at 24 ± 2 months (95% CI) was 2.01 (1.17, 3.43) for 
“threshold 200” and 1.24 (0.89, 1.73) for “threshold 350”. The risk ratios at 18 ± 2 months (95% CI) and 
from alternative definitions of virologic suppression were closer to the null (Appendix Page 7), but the 
95% confidence intervals were wide. 
CD4 cell count 
The mean baseline CD4 cell count was 413 cells/µl. At 24 months, the mean CD4 cell count (95% CI) 
was 504.4 cells/µl (446.0, 570.5) for “threshold 200”, 500.5 cells/µl (446.2, 561.3) for “threshold 350” 
and 504.0 cells/µl (450.5, 563.9) for “threshold 500”. The 24-month mean CD4 cell count difference 
(95% CI) was 0.4 (-25.5, 26.3) cells/µl for “threshold 200” and -3.5 (-16.0, 8.9) cells/µl for “threshold 
350”, compared with “threshold 500” (Appendix Page 9). When adjusting only for baseline confounding, 
the 24-month mean CD4 cell count was larger for “threshold 500” compared with “threshold 200” (533.8 
cells/µl compared with 486.8 cells/µl) (Appendix Page 10). There were no differences in mean CD4 cell 
count at 24 months between the three strategies when excluding individuals presenting late to care, when 
excluding intravenous drug users and those with an unknown mode of transmission, and when restricting 
the analysis to individuals with baseline CD4 cell counts>500 cells/µl (data not shown).  
Discussion  
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Our findings suggest that decreasing monitoring of CD4 cell count and HIV-RNA from every 3-6 months 
to every 9-12 months while CD4 cell count>200 cells/µl does not worsen the 2-year clinical and 
immunologic outcomes of HIV-positive, virologically suppressed individuals on cART without AIDS in 
high-income countries. Our estimates also suggest that decreasing monitoring frequency when CD4 cell 
count>200 cells/µl compared with when CD4 cell count>500 cells/µl results in an increased risk of 
virologic failure at 24 months of follow-up, but the 95% confidence intervals around these estimates were 
wide. Because few individuals followed the strategies of interest for extended periods of time, we were 
not able to assess clinical, immunologic, and virologic outcomes after 2-years of follow-up. 
The individuals following the “threshold 500” strategy were monitored more frequently over follow-up on 
average and had a higher rate of treatment switching compared with those following the “threshold 200” 
strategy, even after adjusting for confounding. Thus one potential explanation for the virologic failure 
finding is that individuals following the “threshold 500” strategy who had virologic failure switched 
treatment and achieved virologic suppression before 24 months of follow-up.  
Some limitations of our study should be noted. Like any other observational study, the validity of our 
estimates relies on the untestable assumption that the measured covariates were sufficient to adjust for 
confounding and selection bias. An imbalance of individuals with poor adherence to cART and to clinic 
visits across the monitoring strategies could lead to bias. For example, physicians might monitor 
individuals perceived to have lower adherence with greater frequency, and individuals with poor 
adherence who maintain a suppressed HIV-RNA and CD4 cell count slightly above 200 cells/µl will 
follow the “threshold 200” strategy for longer than the other strategies. Though data on collection of ART 
prescriptions or more direct adherence measurements were not available in our study, excluding 
subgroups of individuals hypothesized to have low levels of adherence (those who did not achieve 
virologic suppression within 8 months of cART initiation) or perceived adherence (intravenous drug users 
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and those with an unknown mode of transmission) did not affect the results. Still, if these sub-group 
analyses did not adequately exclude individuals with poor adherence, our results could still be biased.  
An imbalance of individuals with low CD4 cell counts across the monitoring strategies could also bias the 
results. Since individuals in our study are monitored frequently over follow-up, regardless of their CD4 
cell count, the “threshold 200” strategy has a higher concentration of individuals with CD4 cell 
count<200 cells/µl than the other strategies. However, the inverse-probability weights function to balance 
the distribution of baseline CD4 cell count across the strategies. 
Our estimates would also be susceptible to bias if individuals monitored more (or less) frequently were 
individuals at later stages of HIV infection, since these sicker patients would also be at a higher risk of 
death. However, an analysis that partially reduces this confounding by excluding individuals presenting 
late to care (initiating cART at a CD4 cell count<200 cells/µl) did not yield appreciably different results. 
Our estimates could also be confounded if individuals are monitored more frequently after a treatment 
regimen switch, but an analysis adjusting for time since first treatment switch did not affect our estimates. 
If individuals with comorbidities visit the clinic more often compared with those who do not our results 
could also be confounded, but adjustment for time since the last clinic visit did not alter the results. Some 
residual confounding due to varying practice patterns among clinical centers is possible because our 
estimates are adjusted for cohort but not for the individual centers within each cohort. 
Clinical guidelines discourage CD4 cell count monitoring for individuals with undetectable HIV-RNA 
and CD4>500 cells/µl for two years.10 While we could not directly compare strategies where CD4 cell 
count monitoring is discontinued while HIV-RNA monitoring is maintained (because CD4 cell count and 
HIV-RNA were usually monitored at the same time in our study), our finding that monitoring frequency 
can be safely decreased with respect to clinical and immunologic outcomes, but not with respect to 
virologic outcomes supports this recommendation.  
14 
 
Non-AIDS defining clinical events contribute substantially to morbidity in HIV-positive individuals on 
successful cART, but were not assessed in this study. While our results support decreasing CD4 cell count 
and HIV-RNA monitoring in healthy populations, regular clinic visits remain critical to assess adherence, 
co-morbidities like HCV coinfection16, and psychosocial needs. Finally, our analysis included individuals 
initiating cART in 2000 or later, yet it is possible that monitoring frequency could have differential effects 
over calendar time as cART guidelines and prescribing patterns evolve.  
Our results support current guidelines7-10 and suggest that the CD4 threshold at which monitoring 
frequency can be decreased to annually may be as low as 200 cells/µl with respect to 2-year clinical and 
immunologic outcomes. However, more frequent virologic monitoring may be necessary to reduce the 
risk of virologic failure. While further research is warranted to obtain more precise effect estimates over 
longer periods of follow-up, our results may be useful to inform clinical practice. 
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Table 1. Characteristics of the individuals at baseline and at 14 months of follow-up, CNICS and HIV-
CAUSAL Collaboration 2000-2015 
 Individuals at 
baseline 
(n=47,635) 
Individuals remaining at 14 months of follow-up (n=16,325) 
 Persons, n (%) 
   “Threshold 
200”  
(n=1,676) 
“Threshold  
350”  
(n=4,824) 
“Threshold  
500”  
(n=9,825) 
Baseline characteristic 
 
    
CD4 cell count (cells/µl)  
 
    
≤200 6,533 (13.7)  1,001 (59.6) 2,282 (46.7) 2,596 (26.0) 
200 to < 350 13,631 (28.6)  234 (13.9) 1,974 (40.4) 4,713 (47.2) 
350 to < 500 14,116 (29.6)  230 (13.7) 412 (8.4) 2,219 (22.2) 
>500 13,355 (28.0)  214 (12.8) 222 (4.5) 450 (4.5) 
Mean, value 413  245 231 284 
Sex       
Male 38,399 (80.6)  1,370 (81.6) 3,867 (79.1) 7,948 (79.7) 
Female 9,236 (19.4)  309 (18.4) 1,023 (20.9) 2,030 (20.3) 
Race      
White 12,607 (26.5)  309 (18.4) 931 (19.0) 2,057 (20.6) 
Black 4,595 (9.7)  168 (10.0) 568 (11.6) 980 (9.8) 
Other/unknown 30,433 (63.9)  1,202 (71.6) 3,391 (69.4) 6,941 (69.6) 
Age (years)      
<35 16,240 (34.1)  491 (29.2) 1,313 (26.9) 2,889 (29.0) 
35-50 22,663 (47.6)  791 (47.1) 2,446 (50.0) 4,945 (49.6) 
>50 8,732 (18.3)  397 (23.7) 1,131 (23.1) 2,144 (21.5) 
Origin       
North America or Western Europe 29,043 (61.0)  1,134 (67.5) 3,015 (61.7) 6,219 (62.3) 
Sub-Saharan Africa 3,325 (7.0)  128 (7.6) 430 (8.8) 839  (8.4) 
Other 3,462 (7.3)  118 (7.0) 358 (7.3) 773 (7.8) 
Unknown 11,805 (24.8)  299 (17.8) 1,087 (22.2) 2,147 (21.5) 
Acquisition group      
Heterosexual 15,122 (31.8)  613 (36.5) 1,839 (37.6) 3,513 (35.2) 
Homo/bisexual 23,370 (49.1)  558 (33.2) 1,715 (35.1) 4,152 (41.6) 
Injection drug User 1,997 (4.2)  135 (8.0) 327 (6.7) 522 (5.2) 
Other/unknown 7,146 (15.0)  373 (22.2) 1,009 (20.6) 1,791 (18.0) 
Calendar year       
2000-2002 4,390 (9.2)  217 (12.9) 639 (13.1) 1,123 (11.3) 
2003-2005 8,334 (17.5)  369 (22.0) 1,215 (24.9) 2,312 (23.2) 
2006-2008 11,529 (24.2)  436 (26.0) 1,450 (29.7) 3,054 (30.6) 
≥2009 23,382 (49.1)  657 (39.1) 1,586 (32.4) 3,489 (35.0) 
Months to suppression      
2-4 16,227 (34.1)  488 (29.1) 1,443 (29.5) 3,035 (30.4) 
5-8 22,676 (47.6)  808 (48.1) 2,480 (50.7) 5,106 (51.2) 
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9-12 8,732 (18.3)  383 (22.8) 967 (19.8) 1,837 (18.4) 
Mean, value 5.9  6.4 6.2 6.1 
Years since HIV diagnosis      
<1 15,602 (32.8)  695 (41.4) 2,114 (43.2) 3,692 (37.0) 
1- < 5 17,114 (35.9)  439 (26.2) 1,204 (24.6) 3,118 (31.3) 
5 or more 5,716 (12.0)  180 (10.7) 629 (12.9) 1,343 (13.5) 
unknown 9,203 (19.3)  365 (21.7) 943 (19.3) 1,825 (18.3) 
Time-varying characteristic 
(measured at 14 months) 
     
Most recent CD4 cell count (cells/µl)       
<200 --  700 (41.7) 938 (19.2) 964 (9.7) 
200 to < 350 --  426 (25.4) 2,438 (49.9) 3,341 (33.5) 
350 to < 500 --  208 (12.4) 1,066 (21.8) 3,898 (39.1) 
≥500 --  345 (20.6) 448 (9.2) 1,775 (17.8) 
Mean, value --  324 316 379 
Most recent HIV-RNA (copies/ml)      
≤200 --  1,525 (90.8) 4,607 (94.2) 9,511 (95.3) 
201-999 --  45 (2.7) 112 (2.3) 204 (2.0) 
1,000-9,999 --  40 (2.4) 66 (1.4) 110 (1.1) 
≥10,000 --  69 (4.1) 105 (2.2) 153 (1.5) 
Mean, value --  5,856 2,685 1,847 
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Table 2. Clinical and virologic outcomes by monitoring strategy, CNICS and HIV-CAUSAL 
Collaboration 2000-2015 
Outcome and monitoring strategy Outcomes, cases Person-months Hazard ratios* (95% CI)   
All-cause mortality    
“Threshold 200” 107 249,597 1.05 (0.86, 1.29) 
“Threshold 350”  157 340,428 1.02 (0.91, 1.14) 
“Threshold 500”  
 
200 490,713 1.00 (reference) 
AIDS-defining illness or death    
“Threshold 200” 267 247,816 1.08 (0.95, 1.22) 
“Threshold 350”  365 337,823 1.03 (0.96, 1.12) 
“Threshold 500”  
 
459 487,232 1.00 (reference) 
Virologic failure 
(RNA>200) at 24 months 
No. faileda  Risk ratios* (95% CI) 
“Threshold 200” 35  2.01 (1.17, 3.43) 
“Threshold 350”  89  1.24 (0.89, 1.73) 
“Threshold 500”  171  1.00 (reference) 
a. Based on 405, 1,610, and 3,962 individuals with HIV-RNA measurements at 24 ± 2 months following the 
“threshold 200”, “threshold 350” and “threshold 500” strategies, respectively. 
*Adjusted for the baseline covariates (sex, age, race, geographic origin, acquisition group, CD4 cell count, 
HIV-RNA, calendar year, years since HIV diagnosis, cohort, and months from cART initiation to virologic 
suppression). We adjusted for potential selection bias induced by artificial censoring using inverse probability 
weighting. 
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Figure 1. Schematic of one of the three dynamic monitoring strategies under the CD4 cell count threshold 
200cells/µl, CNICS and HIV-CAUSAL Collaboration 2000-2015.  
 
 
The other two strategies are identical except that the CD4 cell count threshold is 350 cells/µl in the 2nd 
strategy and 500 cells/µl in the 3rd strategy. 
CD4>200 cells/µl, 
HIV-RNA≤200 copies,
and no AIDS 
at time t
yes
monitor CD4 and RNA 
again after 9-12 months
no
monitor CD4 and RNA 
again after 3-6 months
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Figure 2. Number of individuals following each monitoring strategy over follow-up, CNICS and HIV-CAUSAL Collaboration 2000-2015 
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Figure 3. 24-month survival and AIDS-free survival curves by monitoring strategy, CNICS and HIV-CAUSAL Collaboration 2000-2015 
 
 
The curves are standardized by the baseline covariates: sex, CD4 cell count (≤200, 201-350, 351-500, ≥501 cells/µl), years since HIV diagnosis (<1, 1-4, 
≥5 years, unknown), race (white, black, other or unknown), geographic origin (N. America/W. Europe, Sub-Saharan Africa, other, unknown), acquisition 
group (heterosexual, homosexual or bisexual, injection drug use, other or unknown), calendar year (restricted cubic splines with 3 knots at 2001, 2007 and 
2011), age (restricted cubic splines with 3 knots at 25, 39 and 60 years), cohort, and months from cART initiation to virologic suppression (2-4, 5-8, ≥9). 
We adjusted for potential selection bias induced by artifical censoring using inverse probability weighting.
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Research in context panel 
Evidence before this study 
We searched PubMed and reports from WHO, the Department of Health and Human Services, the 
European AIDS Clinical Society, and the British HIV Association using combinations of the search terms 
“CD4 cell count”, “viral load”, “antiretroviral therapy”, and “monitoring” for articles published in English 
up to January 1, 2017. Two randomized trials and several observational studies have addressed the 
question of when to monitor CD4 cell count and HIV-RNA in HIV-positive individuals on combined 
antiretroviral therapy (cART). The results from the randomized trials were conflicting with respect to the 
main virologic outcome, but the studies defined the monitoring strategies, eligibility criteria, and follow-
up differently. Both the randomized trials and the observational studies did not assess clinical endpoints, 
had short follow-up, and did not compare dynamic monitoring strategies in which monitoring frequency 
depends on an individual’s time-varying CD4 cell count.  
Added value of this study 
We have used observational data from two collaborations of prospective cohort studies from Europe and 
the Americas to compare the effectiveness of three dynamic monitoring strategies applied to virologically 
suppressed HIV-positive individuals. The three strategies differ with respect to the CD4 cell count 
threshold that is used to measure CD4 cell count and HIV-RNA every 3-6 months (when below the 
threshold) or every 9-12 months (when above the threshold). The threshold was 200 cells/µl in the first 
strategy, 350 cells/µl in the second strategy, and 500 cells/µl in the third strategy. In this population we 
found no effect of the monitoring strategies on survival, AIDS-free survival, and 2-year mean CD4 cell 
count, suggesting that decreasing monitoring to annually when CD4 cell count>200 cells/µl compared 
with >500 cells/µl does not worsen the short-term clinical and immunologic outcomes of virologically 
suppressed HIV-positive individuals. However, we found that decreasing monitoring frequency when 
CD4 cell count>200 cells/µl compared with >500 cells/µl results in an increased risk of virologic failure 
at 2 years.  
Implications of all the available evidence 
In virologically suppressed individuals on cART in resource-rich settings, the CD4 threshold at which 
monitoring frequency can be decreased to annually may be as low as 200 cells/µl with respect to clinical 
and immunologic outcomes. However, more frequent virologic monitoring may be necessary to reduce 
the risk of virologic failure. Further research is warranted to obtain more precise effect estimates over 
longer periods of follow-up, and to determine the generalizability of these results to resource-limited 
settings.  
 
 
 
 
 
